


Braingineering Technologies (BTech)

In vitro Disease modeling & Drug Discovery



Brainengineering Technologies – A Team with Complementary Skills



Stephanie Smith-Eckhardt
CEO




Jens Schwamborn
CSO



Silvia Bolognin
CTO

BTech is **>15** years of cumulated experience in



3D Brain-on-a-Chip Technology Helps Our Customers to Find Effective Drugs

Customer Pain Point

- Difficulty to treat neuro-degenerative diseases due to complexity
- Only 8.2% of central neuro system (CNS) drug candidates enter the market after clinical phase (15% across all therapeutic areas)

Why?


Current in vivo (rodents) & in vitro models (2D) fail to mimic the complex human organism

Thus,

Customer Need: validated in vitro models


Prevent selection of non-effective drugs

Prevent missing effective drugs



Video: Edinson Lucumi Moreno, Fleming lab, LCSB

BTech's Fee-for-Service Business Model



**Two ongoing pilot projects with big pharma.
In negotiations for follow-up projects.**